HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

Benzinga · 03/11 10:27
HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $7 price target.